Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR1E | P28566 | 1/20 | 0.48 |
| ▸ | HTR1F | P30939 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18962466 | 0.73 | HTR1D (0.55) | HTR3EHTR3BHTR1AHTR1DHTR1B | |
| SCHEMBL29162324 | 0.73 | HTR3E (0.51) | HTR3EHTR3BHTR1AHTR1DHTR1B | |
| SCHEMBL14070022 | 0.72 | LMNA (0.64) | ALDH1A1MAPTLMNAHPGDHSD17B10 | |
| SCHEMBL29957688 | 0.72 | HTR3E (0.51) | HTR3EHTR3BHTR1AHTR1DHTR1B | |
| SCHEMBL3179154 | 0.72 | HTR3E (0.51) | HTR3EHTR3BHTR1AHTR1DHTR1B | |
| SCHEMBL186914 | 0.71 | CYP2A6 (0.53) | CYP2A6IMPDH2CCNT1CDK9HASPIN | |
| SCHEMBL16727124 | 0.71 | CYP2A6 (0.53) | CYP2A6IMPDH2CCNT1CDK9HASPIN | |
| SCHEMBL29956600 | 0.71 | CYP2A6 (0.53) | CYP2A6IMPDH2CCNT1CDK9HASPIN | |
| SCHEMBL30388511 | 0.70 | KDM4E (0.53) | HTR3EHTR3BHTR1AHTR1DHTR1B | |
| SCHEMBL30668159 | 0.70 | KDM4E (0.53) | HTR3EHTR3BHTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-6831075-B2 | Administering to a host for inhibiting kinase activity a 5-heterocylcic subustituted pyrazolone derivative | CEPHALON, INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1109813-B1 | PYRROLOINDOLES, PYRIDOINDOLES AND AZEPINOINDOLES AS 5-HT2C AGONISTS | VERNALIS RES LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2003-08-28 | — | — | US | disclosed |
| US-6455525-B1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6433175-B1 | ANTISEROTONINE AGENTS | VERNALIS RESEARCH LIMITED (GB) | 2002-08-13 | — | — | US | disclosed |
| EP-1226141-A1 | HETEROCYCLIC SUBSTITUTED PYRAZOLONES | CEPHALON, INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1109813-A1 | PYRROLOINDOLES, PYRIDOINDOLES AND AZEPINOINDOLES AS 5-HT2C AGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001032653-A1 | HETEROCYCLIC SUBSTITUTED PYRAZOLONES | CEPHALON, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000012510-A1 | PYRROLOINDOLES, PYRIDOINDOLES AND AZEPINOINDOLES AS 5-HT2C AGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-1992007829-A1 | INDOLE-3-METHANAMINES USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS | THE UPJOHN COMPANY (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CYP3A4, CYP3A5, PDXK | HTR3E 1560/4885HTR3B 1404/4885HTR1A 2702/4885 |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CDK5, CDK5R1, CDK7 | HTR3E 1354/4885HTR3B 1842/4885HTR1A 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.